H.C. Wainwright raised the firm’s price target on Santhera Pharmaceuticals (SPHDF) to CHF 30 from CHF 25 and keeps a Buy rating on the shares. Santhera remains engaged in various national processes of health technology assessments, pricing negotiations, and reimbursement decisions, the analyst tells investors in a research note. The firm believes vamorolone’s commercial traction continues.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPHDF:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue